Navigation Links
PAREXEL Appoints Leading Central Nervous System Experts to Its Global Clinical Pharmacology Business
Date:4/2/2008

aluations of medications for the treatment of a broad range of CNS and psychiatry disorders. Dr. Ereshefsky is a leader in CNS clinical study design and research methodologies, and has served on U.S. Food and Drug Administration (FDA) and United States Pharmacopeia (USP) advisory boards. Prior to joining PAREXEL, Dr. Ereshefsky was Chief Scientific Officer at California Clinical Trials. He was formerly Professor of Psychiatry and Pharmacology at The University of Texas Health Science Center in San Antonio, Texas in the United States. Previously, he was Associate Director of Research at San Antonio State Hospital, and held principal investigator and clinical consulting positions at several medical institutions. Dr. Ereshefsky received a Pharm.D. degree from the University of Southern California (USC), and completed his residency at the Los Angeles County-USC Medical Center. He currently serves on the Executive Committee of The International Society for CNS Clinical Trials and Methodology, and has served as Presidential Officer of the College of Psychiatric and Neurological Pharmacists. He is a frequent presenter, has authored more than 100 articles, and has held editorial advisory positions for major psychiatry, pharmacologic, and psychiatric pharmacy publications.

Dr. Malek Bajbouj is Board Certified in Psychiatry and Clinical Neurophysiology. He has expertise in CNS biomarkers and the development of new physiological procedures, including neurophysiological and neuroimaging measures used in cognitive function research. His research background also includes genetics, antidepressive stimulation techniques, and sleep medicine. Dr. Bajbouj is a Professor at the Charite University in Berlin, Germany, where he heads the Electroencephalography Lab and Neuromodulation Unit. He also serves as Co-Director of the Affective Disorder Module and the Sleep Laboratory at the university. Dr. Bajbouj is a permanent member of the university's Drug Commission and Doctoral Commi
'/>"/>

SOURCE PAREXEL International Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. PAREXEL International Expands Relationship with Synchron Research in India and Divests Bioanalytical Laboratory in France
2. PAREXEL Announces Date of Third Quarter Fiscal Year 2008 Earnings Release and Conference Call
3. PAREXEL Appoints Leading Biopharmaceutical Marketing Expert Jacque Fisher to Medical Communications Services Executive Team
4. PAREXEL International to Present at Lehman Brothers 11th Annual Global Healthcare Conference
5. PAREXEL International to Present at Raymond James 29th Annual Institutional Investors Conference
6. PAREXEL to Present Leading Insights Regarding Key Industry Topics at 20th Annual Drug Information Association EuroMeeting
7. PAREXEL International Announces 2-For-1 Stock Split
8. PAREXEL Reports Second Quarter Fiscal Year 2008 Financial Results
9. PAREXEL Names Biopharmaceutical Industry Executive Eduard E. Holdener to Board of Directors
10. PAREXEL Announces Date of Second Quarter Fiscal Year 2008 Earnings Release and Conference Call
11. PAREXEL Appoints Charles A. Stevens as Vice President/General Manager of Health Policy and Strategic Reimbursement and Strengthens Capabilities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/13/2014)... The “Global Synthetic Biology Market (2013-2018)”, analyses ... and challenges. , The global synthetic biology market ... Fisher Scientific, Inc. (U.S.), DuPont (U.S.), and Royal ... approximately ~65% of the total synthetic biology market. ... Report @ http://www.marketsandmarkets.com/Market-Reports/synthetic-biology-market-889.html , Thermo Fisher ...
(Date:12/13/2014)...  Vermillion, Inc. (NasdaqCM: VRML), a bio-analytical solutions company focused ... Veronica G. H. Jordan , Ph.D., and David ... bringing the total number of directors to eight, seven ... LaFrance , Chairman, President, and Chief Executive Officer of ... appointments of Veronica and David to our board of ...
(Date:12/13/2014)... SAN ANTONIO , Dec. 12, 2014 /PRNewswire/ ... presentation of data at the San Antonio Breast Cancer ... epoetin alfa plus best supportive care (BSC) versus BSC ... breast cancer receiving standard chemotherapy. This non-inferiority trial did ... out a 15 percent or greater increase in the ...
(Date:12/12/2014)... Pittcon is pleased to announce ... over 2,000 technical presentations offered in symposia, oral ... program covers a wide range of applications such ... discovery, environmental, food science, fuels/energy, genomics, lab management, ... The Technical Program begins on Sunday, March 8 ...
Breaking Biology Technology:Synthetic Biology Market to HIt $5.6304 Billion by 2018 - New Research Report by MarketsandMakets 2Synthetic Biology Market to HIt $5.6304 Billion by 2018 - New Research Report by MarketsandMakets 3Vermillion Strengthens Board of Directors with Appointments of Veronica Jordan, Ph.D., and David Schreiber 2Vermillion Strengthens Board of Directors with Appointments of Veronica Jordan, Ph.D., and David Schreiber 3Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 2Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 3Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 4Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 5Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 6Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 7Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 8Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 9Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 10Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 11Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 12Pittcon Announces a Diverse 2015 Technical Program - Renowned Speakers, Special Symposia and Co-programming 2Pittcon Announces a Diverse 2015 Technical Program - Renowned Speakers, Special Symposia and Co-programming 3
... 2 More than a dozen internationally renowned speakers, ... team, will be coming to New Haven, CT to ... symposium taking place March 23-24, 2009.The roster includes scientists ... creation of two new human embryonic stem cell lines ...
... Cephalon, Inc .,(Nasdaq: CEPH ) today ... worldwide rights to Lupuzor(TM), an investigational medication for the,treatment ... of the ImmuPharma Phase IIb study. Cephalon will assume ... commercialization of,the product. , ImmuPharma ...
... BioMed Realty Trust, Inc. (NYSE: BMR ) ... and year ended December 31, 2008 after the market closes ... Chief Executive Officer, and Kent Griffin, President and Chief Financial ... Pacific Time on Thursday, February 12, 2009 to discuss the ...
Cached Biology Technology:Obama Advisor Joins Connecticut and International Scientists at New Haven Stem Cell Symposium 2Cephalon Exercises Option to License Worldwide Rights to ImmuPharma Product, Lupuzor 2Cephalon Exercises Option to License Worldwide Rights to ImmuPharma Product, Lupuzor 3Cephalon Exercises Option to License Worldwide Rights to ImmuPharma Product, Lupuzor 4Cephalon Exercises Option to License Worldwide Rights to ImmuPharma Product, Lupuzor 5BioMed Realty Trust to Report 2008 Fourth Quarter and Year-End Results 2
(Date:12/5/2014)... Calif. , Dec. 4, 2014 ... has boosted investments in new testing and inspection ... also given rise to a range of innovative ... the requirements of Generation Y, which is generally ... As a result, product development strategies of test ...
(Date:11/21/2014)... According to a new market research report ... Control, Intrusion Detection, Parking Management, Under Vehicle Inspection), End ... - Global Forecasts to 2020", published by MarketsandMarkets, The ... $25 Billion in 2014 and is expected to reach ... 8.69%. Browse 116 market data Tables and ...
(Date:11/18/2014)... 18, 2014  The Secure Identity & Biometrics ... jointly announce the formation of The Airport Entry ... Identity and Biometric Entry and Exit Solutions ... official support from BORDERPOL, the international non-profit organization ... provide expertise regarding border security, traveler and migration ...
Breaking Biology News(10 mins):Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 3
... Institute near Cambridge, supported by the Alzheimer,s Research ... Council (BBSRC), have discovered that the brain,s circuitry ... ageing such as Alzheimer,s disease. The findings were ... Alzheimer,s disease causes nerve cells in the ...
... The Stowers Institute,s Linheng Li Lab has identified the precise ... were published today in the Advance Online Publication of ... of the Institute,s support facilities to develop a new technology ... to monitor the dynamic behavior of stem cells. This technology ...
... NY, December 4, 2008Researchers are taking a closer look ... to demonstrate that inhibiting this biological route suppresses tumor ... ( GEN ). The pathway is involved in angiogenesis, ... part of the PI3/AKT/mTOR pathway, which plays a key ...
Cached Biology News:Maintaining the brain's wiring in aging and disease 2Stowers Institute's Linheng Li Lab expands understanding of bone marrow stem cell niche 2
Human Legumain Affinity Purified Polyclonal Ab...
Human Cystatin F MAb (Clone 292103)...
... Ac-DEVD-CHO is an inhibitor ... The concentration of inhibitor ... activity must be determined ... Ten micromolar inhibitor is ...
Human RELT/TNFRSF19L Affinity Purified Polyclonal Ab...
Biology Products: